JP5936273B2 - 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 - Google Patents

肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 Download PDF

Info

Publication number
JP5936273B2
JP5936273B2 JP2012534356A JP2012534356A JP5936273B2 JP 5936273 B2 JP5936273 B2 JP 5936273B2 JP 2012534356 A JP2012534356 A JP 2012534356A JP 2012534356 A JP2012534356 A JP 2012534356A JP 5936273 B2 JP5936273 B2 JP 5936273B2
Authority
JP
Japan
Prior art keywords
seq
cyp
isoform
amino acid
cytochrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012534356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507924A5 (enExample
JP2013507924A (ja
Inventor
ブライアン エル． ウィリアムソン，
ブライアン エル． ウィリアムソン，
スバシシュ プルカヤスタ，
スバシシュ プルカヤスタ，
Original Assignee
ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド
ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド, ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド filed Critical ディーエイチ テクノロジーズ デベロップメント プライベート リミテッド
Publication of JP2013507924A publication Critical patent/JP2013507924A/ja
Publication of JP2013507924A5 publication Critical patent/JP2013507924A5/ja
Application granted granted Critical
Publication of JP5936273B2 publication Critical patent/JP5936273B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012534356A 2009-10-16 2010-10-14 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量 Expired - Fee Related JP5936273B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25243009P 2009-10-16 2009-10-16
US61/252,430 2009-10-16
US25264809P 2009-10-17 2009-10-17
US61/252,648 2009-10-17
PCT/US2010/052665 WO2011047150A1 (en) 2009-10-16 2010-10-14 Mass spectrometry quantitation of p450 protein isoforms in hepatocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016074921A Division JP6116730B2 (ja) 2009-10-16 2016-04-04 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量

Publications (3)

Publication Number Publication Date
JP2013507924A JP2013507924A (ja) 2013-03-07
JP2013507924A5 JP2013507924A5 (enExample) 2013-11-28
JP5936273B2 true JP5936273B2 (ja) 2016-06-22

Family

ID=43876537

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012534356A Expired - Fee Related JP5936273B2 (ja) 2009-10-16 2010-10-14 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量
JP2016074921A Active JP6116730B2 (ja) 2009-10-16 2016-04-04 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016074921A Active JP6116730B2 (ja) 2009-10-16 2016-04-04 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量

Country Status (5)

Country Link
US (3) US8940545B2 (enExample)
EP (2) EP2862870B1 (enExample)
JP (2) JP5936273B2 (enExample)
CA (1) CA2777690C (enExample)
WO (1) WO2011047150A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012056880A (ja) * 2010-09-08 2012-03-22 Idemitsu Kosan Co Ltd インドロカルバゾール化合物、有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
WO2014096914A1 (en) * 2012-12-20 2014-06-26 Dh Technologies Development Pte. Ltd. Scheduled ms3 for quantitation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538262A (ja) * 2004-05-19 2007-12-27 アプレラ コーポレイション 質量分析を使用する発現の定量化
US20080206737A1 (en) 2004-05-19 2008-08-28 Hunter Christie L Expression quantification using mass spectrometry
US20080020673A1 (en) * 2005-03-08 2008-01-24 Cara Sills Doll having hand-assemblable costume
US20070092926A1 (en) 2005-10-14 2007-04-26 Alterman Michail A Analysis of protein isoforms using unique tryptic peptides by mass spectrometry and immunochemistry
JP5299956B2 (ja) * 2008-09-29 2013-09-25 国立大学法人東北大学 質量分析装置を用いた代謝酵素群の一斉タンパク質定量に用いるペプチド

Also Published As

Publication number Publication date
JP6116730B2 (ja) 2017-04-19
US8940545B2 (en) 2015-01-27
US20110091981A1 (en) 2011-04-21
EP2862870A3 (en) 2015-08-12
EP2862870B1 (en) 2020-08-12
WO2011047150A1 (en) 2011-04-21
CA2777690C (en) 2019-05-21
US20150140600A1 (en) 2015-05-21
EP2488545A4 (en) 2013-05-15
JP2013507924A (ja) 2013-03-07
US20150045256A1 (en) 2015-02-12
EP2488545B1 (en) 2014-12-24
JP2016119915A (ja) 2016-07-07
US9546393B2 (en) 2017-01-17
EP2488545A1 (en) 2012-08-22
CA2777690A1 (en) 2011-04-21
EP2862870A2 (en) 2015-04-22

Similar Documents

Publication Publication Date Title
Kettenbach et al. Absolute quantification of protein and post-translational modification abundance with stable isotope–labeled synthetic peptides
Kitteringham et al. Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics
Weiß et al. Direct quantification of cytochromes P450 and drug transporters—a rapid, targeted mass spectrometry-based immunoassay panel for tissues and cell culture lysates
Cooke et al. Evaluation of enzyme-linked immunosorbent assay and liquid chromatography–tandem mass spectrometry methodology for the analysis of 8-oxo-7, 8-dihydro-2′-deoxyguanosine in saliva and urine
Chornoguz et al. mTORC1 promotes T-bet phosphorylation to regulate Th1 differentiation
Schoenherr et al. Multiplexed quantification of estrogen receptor and HER 2/N eu in tissue and cell lysates by peptide immunoaffinity enrichment mass spectrometry
Sato et al. Protein quantification of UDP-glucuronosyltransferases 1A1 and 2B7 in human liver microsomes by LC-MS/MS and correlation with glucuronidation activities
Shao et al. Minimal sample requirement for highly multiplexed protein quantification in cell lines and tissues by PCT‐SWATH mass spectrometry
Weiß et al. Indirect protein quantification of drug-transforming enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry
Youdim et al. An automated, high-throughput, 384 well Cytochrome P450 cocktail IC50 assay using a rapid resolution LC–MS/MS end-point
Kontostathi et al. Development and validation of multiple reaction monitoring (MRM) assays for clinical applications
Williamson et al. Quantitative protein determination for CYP induction via LC‐MS/MS
JP6116730B2 (ja) 肝実質細胞中のｐ４５０タンパク質のアイソフォームの質量分析による定量
Fu et al. Multiple and selective reaction monitoring using triple quadrupole mass spectrometer: preclinical large cohort analysis
Yang et al. A liquid chromatography–tandem mass spectrometry-based targeted proteomics assay for monitoring P-glycoprotein levels in human breast tissue
Sridar et al. Quantitation of UGT1A1 in human liver microsomes using stable isotope-labelled peptides and mass spectrometry based proteomic approaches
Thompson et al. Investigation of oxidative phosphorylation activity and complex composition in mitochondrial disease
Zhi et al. Selected reaction monitoring (SRM) mass spectrometry without isotope labeling can be used for rapid protein quantification
Weng et al. Targeted biomarker quantitation by LC-MS
She et al. Quantification of protein isoforms in mesenchymal stem cells by reductive dimethylation of lysines in intact proteins
CN102175804A (zh) Cyp450酶亚型生物质谱绝对定量方法
Kerfoot et al. Tryptic peptide screening for primary immunodeficiency disease by LC/MS‐MS
Wright et al. Minimalistic sample preparation strategies for LC–MS quantification of large molecule biopharmaceuticals: a case study highlighting alpha-1 antitrypsin protein
Sun et al. Deep Blood Proteomics Identifies over 12,000 Proteins Providing Valuable Information about the State of the Human Body
Wiśniewski Dilemmas With Absolute Quantification of Pharmacologically Relevant Proteins Using Mass Spectrometry

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20131011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160404

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160506

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160509

R150 Certificate of patent or registration of utility model

Ref document number: 5936273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees